AbbVie ABBV announced that the European Commission has approved Aquipta (atogepant) for the acute treatment of migraine in ...

One class of drugs has already found success in treating the painful, disorienting and common attacks. Excitement is building about a slew of additional drug targets. By Amber Dance/Knowable Magazine ...

European Commission approves AbbVie’s Aquipta for the acute treatment of migraine in adults: North Chicago, Illinois Wednesday, June 3, 2026, 11:00 Hrs [IST] AbbVie announced th ...

BARCELONA — Restarting an anti-CGRP monoclonal antibody (mAb) for migraine prevention after a gap in treatment often leads to a lower efficacy rate in the second treatment period, a new study suggests ...

The decision is supported by results from the Phase III ECLIPSE study, which assessed Aquipta versus placebo for migraine.

3D render of a man with strong pain in head – Grayscale Image Researchers compared the safety and efficacy of drugs indicated for preventing migraine. Calcitonin gene-related peptide or its receptor ...

Insights from AHS 2026, including anticipated presentations, key takeaways, and how new research in migraine treatment will affect patient care.

Brise Pharmaceutical (Shanghai) Co. Ltd. has identified calcitonin gene-related peptide (CGRP) receptor antagonists reported to be useful for treatment of cerebrovascular and vascular disorders.

Please provide your email address to receive an email when new articles are posted on . CGRP inhibitors used to treat migraine did not increase glaucoma risk. Monoclonal antibody CGRP inhibitors were ...